| # | Title | Journal | Year | Citations |
|---|
| 1 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) | Lancet, The | 2017 | 1,032 |
| 2 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial | Lancet, The | 2012 | 856 |
| 3 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial | Lancet, The | 2021 | 552 |
| 4 | Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review | Oncologist | 2012 | 265 |
| 5 | Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab | Clinical Cancer Research | 2018 | 222 |
| 6 | Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome | Histopathology | 2016 | 177 |
| 7 | Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer | Annals of Oncology | 2016 | 129 |
| 8 | Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study | Lancet Oncology, The | 2019 | 125 |
| 9 | Characterization of progesterone receptor A and B expression in human breast cancer | Cancer Research | 1995 | 124 |
| 10 | Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients | Journal of Vascular and Interventional Radiology | 2012 | 122 |
| 11 | Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma | Journal of Thoracic Oncology | 2017 | 121 |
| 12 | High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy | BJU International | 2012 | 80 |
| 13 | Gaps in Optimal Care for Lung Cancer | Journal of Thoracic Oncology | 2008 | 77 |
| 14 | Preferential Stimulation of Human Progesterone Receptor B Expression by Estrogen in T-47D Human Breast Cancer Cells | Journal of Biological Chemistry | 1995 | 75 |
| 15 | Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma | Journal of Thoracic Oncology | 2018 | 75 |
| 16 | Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds | Oncogene | 1995 | 69 |
| 17 | Hospitalised patients' views on doctors and white coats | Medical Journal of Australia | 2001 | 67 |
| 18 | Cognitive Function in Breast Cancer Survivors | Cancer Treatment and Research | 2009 | 66 |
| 19 | The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition | Cancer | 2014 | 65 |
| 20 | Inhibitors of mTOR | Oncologist | 2010 | 60 |
| 21 | OA 17.06 Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50% | Journal of Thoracic Oncology | 2017 | 60 |
| 22 | Beauty is in the eye of the examiner: reaching agreement about physical signs and their value | Internal Medicine Journal | 2005 | 59 |
| 23 | Estradiol induction of retinoic acid receptors in human breast cancer cells | Cancer Research | 1993 | 58 |
| 24 | The evolution of chemotherapy for the treatment of prostate cancer | Annals of Oncology | 2017 | 57 |
| 25 | LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial | Annals of Oncology | 2020 | 56 |
| 26 | Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic | JCO Oncology Practice | 2020 | 56 |
| 27 | Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience | Supportive Care in Cancer | 2013 | 53 |
| 28 | Screening for ROS1 gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target | Histopathology | 2017 | 52 |
| 29 | EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors | Journal of Thoracic Oncology | 2017 | 52 |
| 30 | Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma | Oncogene | 1994 | 48 |
| 31 | Certain Death in Uncertain Time: Informing Hope by Quantifying a Best Case Scenario | Journal of Clinical Oncology | 2010 | 44 |
| 32 | Colorectal cancer survivorship: A systematic review and thematic synthesis of qualitative research | European Journal of Cancer Care | 2021 | 43 |
| 33 | PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma | Pathology | 2017 | 39 |
| 34 | Adverse Tumor Biology Associated with Mesenterico-Portal Vein Resection Influences Survival in Patients with Pancreatic Ductal Adenocarcinoma | Annals of Surgical Oncology | 2014 | 36 |
| 35 | Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy | Pigment Cell and Melanoma Research | 2018 | 34 |
| 36 | Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) | Scientific Reports | 2019 | 34 |
| 37 | Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series | Internal Medicine Journal | 2015 | 32 |
| 38 | Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres | Journal of Vascular and Interventional Radiology | 2010 | 30 |
| 39 | The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine | Lung Cancer | 2012 | 30 |
| 40 | Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma | Neoplasia | 2016 | 30 |
| 41 | Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long‐term follow‐up | BJU International | 2017 | 30 |
| 42 | Leptomeningeal melanoma—A case series in the era of modern systemic therapy | Pigment Cell and Melanoma Research | 2018 | 29 |
| 43 | Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer | British Journal of Cancer | 2011 | 28 |
| 44 | Lost in translation: returning germline genetic results in genome-scale cancer research | Genome Medicine | 2017 | 27 |
| 45 | Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II) | Melanoma Research | 2020 | 27 |
| 46 | A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer | Lung Cancer | 2020 | 27 |
| 47 | Validation of tissue microarray technology in malignant pleural mesothelioma | Pathology | 2011 | 26 |
| 48 | e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer | European Journal of Cancer Care | 2017 | 25 |
| 49 | Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay | Nanotheranostics | 2020 | 25 |
| 50 | INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival | Prostate | 2015 | 24 |
